Table 1.
Characteristic of CML Patients (n = 52)
| Characteristic | Value |
|---|---|
| Age, years | |
| Median (range) | 36 (2–74) |
| Mean ± SD | 36.9 ± 19.28 |
| Age group, n (%) | |
| <40 years | 28 (53.9) |
| 40–59 years | 19 (36.5) |
| ≥60 years | 5 (9.6) |
| Sex, n (%) | |
| Male | 33 (63.5) |
| Female | 19 (36.5) |
| Disease phase, n (%) | |
| Chronic phase (CP) | 38 (73.1) |
| Accelerated phase (AP) | 4 (7.7) |
| Blast phase (BP) | 8 (15.4) |
| N.A | 2 (3.8) |
| Current TKI therapy, n (%) | |
| Imatinib | 41 (79) |
| Nilotinib | 9 (17) |
| Ponatinib | 2 (4) |
| Laboratory parameters, mean ± SD (range) | |
| Hemoglobin, g/dL | 12 ± 1.96 (5.5–13.4) |
| White blood cell count (×103/uL) | 16 ± 27.7 (17.9–607.4) |
| Platelet count (×109/L) | 528 ± 820 (18–5658) |
| BCR-ABL1 IS (%), median (range) | 98% (0.018–193%) |
Abbreviation: N.A, The data is not available.